Martin David Harp

Susvimo 100 mg/mL for intravitreal use via ocular implant is a refillable implant surgically inserted into the eye during a one-time, outpatient procedure, continuously delivering a customized formulation of ranibizumab over time.

Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.

Laru-zova is a gene therapy currently being investigated for the treatment of patients with X-linked retinitis pigmentosa.

The device recently received 510(k) clearance from the US Food and Drug Administration.

Zhaoke Ophthalmology Limited is responsible for developing and obtaining regulatory approval for NVK-002 in Greater China, South Korea, and the Southeast Asian territories.

The Sentinel Camera aims to address critical gaps in retinal disease screening by offering a portable device that captures high-quality images that require no dilation of the eye.

The approval of Syfovre makes it the first and only approved treatment for GA in Australia.

The meetings support the company’s submission for its bioengineered corneal implants to eliminate corneal blindness.

ARCATUS or ARVN001, in Greater China, South Korea, Australia, New Zealand, India and the ASEAN Countries is formally known as XIPERE in the United States and was developed by Clearside Biomedical.

Topline data results are expected in February 2025.

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.

The phase 1 clinical trial is a multicenter, open-label, dose-escalation study to assess drug safety via intravitreal injection in 3 cohorts.

The trial evaluated ONS-5010 in wet age-related macular degeneration patients, and the company plans to resubmit a Biologics License Application in the first quarter of 2025.

The launch follows a CE Mark received late last year.

Whitecap is currently developing 2 therapies for potential use in glaucoma and geographic atrophy.

The Loong Crystal PR IOL is designed for the treatment of myopia in adults ranging from -3.25D to -18.00D.

The financing will go toward its ongoing phase 2b/3 and planned pivotal phase 3 clinical trial for AVD-104.

The long-term analysis show clinically and statistically significant reductions in intraocular pressure through up to 36 months postoperatively.

The company also released additional data from its phase 2 clinical trial in addition to the LONGITUDE program design.

The campaign will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness and encourage proactive eye health management.

The primary safety endpoint was carried out through the percentage of patients with shift from normal (at baseline) to abnormal in any electrocardiogram (ECG).

A study conducted with over 77,000 individuals found that alcohol consumption increased the risk of dry eye in women.

The trial is evaluating GAL-101 eye drops in patients with geographic atrophy, an advanced form of dry AMD.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

A look at the biggest news and advancements in ophthalmology in 2024.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.

This series features experts in ophthalmology sharing their thoughts on the one unsolved challenge they wish there was a solution for.